FDA Urged to Protect Women from Black Cohosh Supplements

CSPI Says Herbal Supplement Linked to Cancer Spread, Liver Failure
The Food and Drug Administration (FDA) should warn women that preliminary
research suggests that the herbal supplement black cohosh may increase the
risks of breast cancer metastasis and liver failure, according to the Center
for Science in the Public Interest (CSPI). CSPI also called on the National
Institutes of Health, which is studying the effectiveness of black cohosh
in relieving hot flashes and other symptoms of menopause, to advise study
subjects of the possible risks and to be on alert for any adverse effects.
Drug and supplement makers are increasingly marketing black cohosh to menopausal
women in the wake of the safety concerns raised over hormone replacement
therapy. In mice given black cohosh, breast cancer was more likely to spread to the lungs, according to a new study
that CSPI forwarded to the FDA. And at least three cases in the medical
literature have linked liver toxicity in women to herbal remedies containing
black cohosh. Two of the women required liver transplants to survive. Although
labels for many commercial preparations of black cohosh warn that pregnant
or nursing mothers should not take it, no labels warn about risk of cancer
or liver problems. “Women, particularly women who have had breast cancer,
should think twice before taking black cohosh,” said CSPI senior nutritionist
David Schardt. In a letter to FDA Commissioner Mark McClellan,
CSPI said that the FDA should also notify physicians about the potential
risks of black cohosh, and urge them to submit any data on liver toxicity
or cancer metastasis from patients taking black cohosh.
“Women taking black cohosh should be monitored for evidence
of liver problems,” said Stanley M. Cohen, M.D., of Rush Medical Center in
Chicago. “If physicians look for this, we’ll be seeing more cases.” Cohen reported a case of hepatitis in a patient who took black cohosh for three weeks.
Concerns
over hormone replacement therapy were renewed last week when a second government-sponsored
study was halted for safety reasons. According to CSPI, supplement manufacturers
may again be eager to exploit those concerns and aggressively market black
cohosh as a substitute.
 |